Cancer NetworkOriginal article
<![CDATA[Chemoimmunotherapy Combo Exhibits Deep Pathologic Response in HNSCC]]>
Data ReadoutpositivePositive
AI Analysis
Summary
A retrospective cohort study demonstrated that neoadjuvant chemoimmunotherapy achieved deep pathologic response in 67.0% of patients with resectable head and neck squamous cell carcinoma (HNSCC).
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Neoadjuvant chemoimmunotherapy produced a deep pathologic response in 67.0% of patients with resectable HNSCC in retrospective cohort study
Importance:4/10
Sentiment:
0.60
HNSCCchemoimmunotherapyneoadjuvantpathologic responseretrospective study
Read the original article
Published by Cancer Network on August 17, 2026 8:00 PM